XBIT - NASDAQ
XBiotech Inc.
$2.39
-0.27%XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
At a Glance
Live Snapshotxbit
Total Assets
Last Annual Value
150.08M
3-Year CAGR
-15%
5-Year CAGR
-16%
10-Year CAGR
3%
XBiotech Inc. Competitors Analysis of Total Assets
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
XBiotech Inc. NASDAQ:XBIT | 150.08M | -12.8% | -11.4% | 8.4% | |
 Clene Inc. NASDAQ:CLNN | 18.13M | -29.8% | -22.1% | N/A | |
 MindWalk Holdings Corp. NASDAQ:HYFT | 44.44M | -17.0% | -7.9% | 41.5% | |
 Immix Biopharma, Inc. NASDAQ:IMMX | 104.84M | 73.9% | 41.9% | N/A | |
 PMV Pharmaceuticals, Inc. NASDAQ:PMVP | 116.56M | -22.7% | -18.9% | N/A | |
 Vaxart, Inc. NASDAQ:VXRT | 186.08M | 26.5% | -3.4% | 16.6% | |
 Lite Strategy, Inc. NASDAQ:LITS | 18.29M | -46.7% | -36.3% | N/A | |
 Nutriband Inc. NASDAQ:NTRB | 7.47M | -0.2% | -10.1% | 69.7% | |
 Relmada Therapeutics, Inc. NASDAQ:RLMD | 94.00M | -1.2% | -15.9% | 41.9% | |
 CervoMed Inc. NASDAQ:CRVO | 43.08M | 62.9% | 2.6% | 9.4% | |
 Fortress Biotech, Inc. NASDAQ:FBIO | 185.55M | 3.5% | -14.1% | 0.8% |
XBiotech Inc. Fair Value Envelope
Related Guides
Continue your XBIT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.